Hope Rugo: MBC HER2+ PHILA study presented at SABCS 2024
Hope Rugo, Professor of Medicine at UCSF, shared a post on X:
“Pyrotonib improves PFS and OS with docetaxel compared to TH in China in the MBC HER2+ PHILA study but 48% grade 3 diarrhea. No Pertuzumab complicates assessment. But less expensive option in China?”
More posts featuring Hope Rugo.
Read the post “Highlights from Day 1 of SABCS 2024” on oncodaily.com.
Dr. Hope Rugo, MD, FASCO, is a professor of medicine at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center. With experience in hematology and oncology, she specializes in breast cancer treatment and clinical trials.
Dr. Rugo’s research focuses on innovative therapies and combination treatments to improve outcomes for breast cancer patients, including immunotherapy and targeted agents. She is known for her contributions to reducing treatment toxicity educating through initiatives like the Breast Forum.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023